Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | G6PD | P11413 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | WRN | Q14191 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2267710 | 0.77 | GSK3B (0.38) | MGLLGSK3AGSK3BDDAH1 | |
| SCHEMBL20719998 | 0.73 | GSK3A (0.35) | MGLLGSK3AGSK3BALDH1A1CYP1A2 | |
| SCHEMBL711961 | 0.71 | NSD2 (0.41) | MGLLGSK3AGSK3BDDAH1NSD2 | |
| SCHEMBL317849 | 0.69 | DDAH1 (0.39) | MGLLGSK3AGSK3BDDAH1NSD2 | |
| SCHEMBL5551330 | 0.69 | ALDH1A1 (0.31) | GSK3AGSK3BALDH1A1CYP1A2HPGD | |
| SCHEMBL10314831 | 0.68 | GSK3B (0.32) | GSK3B | |
| SCHEMBL720720 | 0.67 | MGLL (0.43) | MGLLGSK3AGSK3BDDAH1NSD2 | |
| SCHEMBL28570540 | 0.67 | P2RX4 (0.37) | MGLLGSK3AGSK3BDDAH1NSD2 | |
| SCHEMBL2801370 | 0.67 | LMNA (0.43) | MGLLGSK3AGSK3BDDAH1NSD2 | |
| SCHEMBL10776987 | 0.64 | GSK3B (0.36) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1443963-B1 | ANTIBODY TARGETING COMPOUNDS | SCRIPPS RESEARCH INST (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20130171074-A1 | TARGETING COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-07-04 | — | — | US | disclosed |
| US-8252902-B2 | Complexing antigen, antibodies; immunoassay | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2428226-A1 | Antibody targeting compounds | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-03-14 | — | — | EP | disclosed |
| CN-100560131-C | Antibody targeting compounds | SCRIPPS RESEARCH INST (US) | 2009-11-18 | — | — | CN | disclosed |
| EP-1443963-A4 | ANTIBODY TARGETING COMPOUNDS | SCRIPPS RESEARCH INST (US) | 2007-09-19 | — | — | EP | disclosed |
| CN-1606454-A | Antibody targeting compounds | SCRIPPS RESEARCH INST (US) | 2005-04-13 | — | — | CN | disclosed |
| WO-2004091542-A2 | NITROGEN CONTAINING INTEGRIN TARGETING COMPOUNDS | COVX PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-1443963-A2 | ANTIBODY TARGETING COMPOUNDS | The Scripps Research Institute (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030190676-A1 | Antibody targeting compounds | THE SCRIPPS RESEARCH INSTITUTE (US) | 2003-10-09 | — | — | US | disclosed |
| US-20030175921-A1 | Antibody targeting compounds | THE SCRIPPS RESEARCH INSTITUTE | 2003-09-18 | — | — | US | disclosed |
| WO-2003059251-A2 | ANTIBODY TARGETING COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030175921-A1 | Antibody targeting compounds | CD47, CD22, FCGR2A | MGLL 4286/4885GSK3A 1635/4885GSK3B 1702/4885 |
| US-20130171074-A1 | TARGETING COMPOUNDS | CD47, CD22, FCGR2A | MGLL 4422/4885GSK3A 2009/4885GSK3B 1983/4885 |
| US-20030190676-A1 | Antibody targeting compounds | CD47, CD22, FCGR2A | MGLL 4286/4885GSK3A 1635/4885GSK3B 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.